Published in Biochem Biophys Res Commun on July 16, 2004
Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration. Antimicrob Agents Chemother (2009) 0.77
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 2.71
Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother (2006) 2.41
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther (2005) 1.82
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother (2008) 1.79
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol (2008) 1.78
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther (2003) 1.78
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol (2005) 1.52
Current status and challenges of antiretroviral research and therapy. Antiviral Res (2009) 1.52
Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age. Eur J Clin Pharmacol (2006) 1.51
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol (2009) 1.49
Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Nephrol Dial Transplant (2008) 1.41
Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther (2003) 1.39
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J (2006) 1.37
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos (2002) 1.36
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther (2006) 1.30
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One (2013) 1.29
Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol (2003) 1.28
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J (2005) 1.28
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother (2007) 1.27
Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol (2007) 1.26
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit (2011) 1.24
Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. J Mol Biol (2010) 1.23
Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health (2005) 1.23
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One (2008) 1.22
Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol (2004) 1.19
Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract (2010) 1.16
Novel targets for HIV therapy. Antiviral Res (2008) 1.15
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother (2006) 1.14
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother (2006) 1.14
Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Eur J Clin Pharmacol (2009) 1.14
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther (2004) 1.12
GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res (2008) 1.10
Pilot study to assess the influence of an enhanced medication plan on patient knowledge at hospital discharge. Eur J Clin Pharmacol (2014) 1.10
Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther (2007) 1.09
Marked differences in the prevalence of chloroquine resistance between urban and rural communities in Burkina Faso. Acta Trop (2007) 1.09
Patients' beliefs about medicines in a primary care setting in Germany. J Eval Clin Pract (2010) 1.06
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos (2006) 1.06
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother (2011) 1.04
Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol (2009) 1.02
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol (2011) 1.01
Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors. Bioorg Med Chem (2008) 1.00
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther (2014) 1.00
Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol (2004) 0.99
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother (2011) 0.99
Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol (2008) 0.97
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol (2003) 0.97
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem (2015) 0.97
In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob Agents Chemother (2011) 0.96
Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother (2005) 0.96
Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother (2013) 0.95
Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics (2011) 0.94
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.94
Induction of multiple drug transporters by efavirenz. J Pharmacol Sci (2009) 0.93
7-Aminoactinomycin D for apoptosis staining in flow cytometry. Anal Biochem (2012) 0.93
Prevention of intravenous drug incompatibilities in an intensive care unit. Am J Health Syst Pharm (2008) 0.92
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol (2004) 0.92
Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol (2009) 0.92
Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol (2004) 0.92
Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother (2010) 0.91
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J (2013) 0.91
Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol (2004) 0.91
Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrob Agents Chemother (2007) 0.90
Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents (2013) 0.90
Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health (2010) 0.90
Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos (2005) 0.89
Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther (2003) 0.89
Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med (2010) 0.88
Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br J Clin Pharmacol (2002) 0.88
In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.87
Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilization. BMC Health Serv Res (2014) 0.87
Can a feedback report and training session on medication counseling for general practitioners improve patient satisfaction with information on medicines? Patient Prefer Adherence (2012) 0.87
Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol (2013) 0.86
Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. Br J Clin Pharmacol (2004) 0.86
Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol (2010) 0.86
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol (2012) 0.85
No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother (2010) 0.85
Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: involvement of pregnane X-receptor. PLoS Negl Trop Dis (2012) 0.84
A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. Eur J Med Chem (2011) 0.84